stockrow
Saturday 7 November 2026
Export TSHA’s income statement to Excel — free account
Taysha Gene Therapies, Inc.
TSHA Healthcare Biotechnology
Taysha Gene Therapies, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.8 million, up 17.3% from fiscal 2024.
- Revenue
- +206.8%
- EPS
- −44.4%
- Free cash flow
- −100.3%
- Total debt
- +20.0%
Quarter to June 2026, against a year earlier
4.35
0.26
+6.36%
Follow TSHA
Alert me
Taysha Gene Therapies, Inc. (TSHA) P/E ratio
Taysha Gene Therapies, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2025 | 0.0× | — |
| Jun 2025 | 0.0× | — |
| Mar 2025 | 0.0× | — |
| Dec 2024 | 0.0× | — |
| 8 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| TSHA Taysha Gene Therapies, Inc. | n/m |
| MLYS Mineralys Therapeutics, Inc. compare | n/m |
| URGN Urogen Pharma compare | n/m |
| KRSA Korsana Biosciences, Inc. compare | n/m |
| GHRS GH Research PLC compare | n/m |
| KARD KARDIGAN INC compare | n/m |
| GPCR Structure Therapeutics Inc. Sponsored ADR compare | n/m |
| ANAB AnaptysBio, Inc. compare | n/m |
| DMRA Galecto, Inc. compare | 24.7× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)